Format

Send to

Choose Destination
PLoS One. 2017 Aug 2;12(8):e0181585. doi: 10.1371/journal.pone.0181585. eCollection 2017.

Progress towards a public chemogenomic set for protein kinases and a call for contributions.

Author information

1
Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
2
AstraZeneca, Darwin Building, Cambridge Science Park, Cambridge, United Kingdom.
3
Drug Discovery Group, Translational Research Office, University College London School of Pharmacy, 29-39 Brunswick Square, London, United Kingdom.
4
Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
5
Peggy and Harold Katz Family Drug Discovery Center, University of Miami Miller School of Medicine, Miami, Florida, United States of America.
6
Laboratory for Molecular Modeling, Division of Chemical Biology and Medicinal Chemistry, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
7
Structural Genomics Consortium, Universidade Estadual de Campinas-UNICAMP, Campinas, Sao Paulo, Brazil.
8
Boehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
9
Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
10
Structural Genomics Consortium and Target Discovery Institute, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, United Kingdom.
11
Harvard Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States of America.
12
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America.
13
Structural Genomics Consortium, Buchmann Institute for Molecular Life Sciences, and Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Straße 15, Frankfurt am Main, Germany.
14
Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 8, Tübingen, Germany.
15
Bayer Pharma AG, Drug Discovery, Müllerstrasse 178, Berlin, Germany.
16
Oncology Chemistry, AbbVie, 1 North Waukegan Road, North Chicago, Illinois, United States of America.
17
Worldwide Medicinal Chemistry, Pfizer Inc., Cambridge, Massachusetts, United States of America.
18
Global Research Externalization, Takeda California, Inc., 10410 Science Center Drive, San Diego, California, United States of America.
19
DiscoverX Corporation,Fremont, California, United States of America.

Abstract

Protein kinases are highly tractable targets for drug discovery. However, the biological function and therapeutic potential of the majority of the 500+ human protein kinases remains unknown. We have developed physical and virtual collections of small molecule inhibitors, which we call chemogenomic sets, that are designed to inhibit the catalytic function of almost half the human protein kinases. In this manuscript we share our progress towards generation of a comprehensive kinase chemogenomic set (KCGS), release kinome profiling data of a large inhibitor set (Published Kinase Inhibitor Set 2 (PKIS2)), and outline a process through which the community can openly collaborate to create a KCGS that probes the full complement of human protein kinases.

PMID:
28767711
PMCID:
PMC5540273
DOI:
10.1371/journal.pone.0181585
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center